Suppr超能文献

[西妥昔单抗和托珠单抗序贯治疗儿童特发性多中心Castleman病:一例报告]

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].

作者信息

Yi Ping, Zhang Xing-Xing, Tang Tian, Wang Ying, Wu Xiao-Chuan, Li Xing-Fang

机构信息

Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha 410011, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2025 May 15;27(5):613-617. doi: 10.7499/j.issn.1008-8830.2412050.

Abstract

The patient, an 11-year-old girl, was admitted with recurrent fever for 20 days, worsening with abdominal distension for 7 days. Upon admission, she presented with recurrent fever, lymphadenopathy, hepatosplenomegaly, polyserositis, and multiple organ dysfunction. Lymph node pathology and clinical manifestations confirmed the diagnosis of idiopathic multicentric Castleman disease-TAFRO syndrome. Treatment with siltuximab combined with glucocorticoids was initiated, followed by maintenance therapy with tocilizumab. The patient is currently in complete clinical remission. Therefore, once a child is diagnosed with idiopathic multicentric Castleman disease -TAFRO syndrome, early use of siltuximab should be considered for rapid disease control, followed by tocilizumab for maintenance therapy.

摘要

该患者为一名11岁女孩,因反复发热20天入院,伴腹胀加重7天。入院时,她表现为反复发热、淋巴结病、肝脾肿大、多浆膜炎和多器官功能障碍。淋巴结病理及临床表现确诊为特发性多中心Castleman病-TAFRO综合征。开始使用西妥昔单抗联合糖皮质激素治疗,随后用托珠单抗进行维持治疗。患者目前处于完全临床缓解状态。因此,一旦儿童被诊断为特发性多中心Castleman病-TAFRO综合征,应考虑早期使用西妥昔单抗以快速控制病情,随后用托珠单抗进行维持治疗。

相似文献

本文引用的文献

1
2
[Progress in the diagnosis and treatment of Castleman disease].[Castleman病的诊断与治疗进展]
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):697-700. doi: 10.3760/cma.j.issn.0253-2727.2020.08.017.
8
Review of siltuximab in the treatment of multicentric Castleman's disease.西妥昔单抗治疗多中心性Castleman病的综述。
Ther Adv Hematol. 2016 Dec;7(6):360-366. doi: 10.1177/2040620716653745. Epub 2016 Jun 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验